ALPHA fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Pharnext SA develops and manufactures drugs for neurological diseases. Its products include R&D Pipeline, PXT3003, and PXT864 are used for the treatment of Charcot-Marie-Tooth disease, diabetic, and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral neuropathies. The company was founded in 2007 by Daniel Cohen, Loic Heidsieck, Serguei Nabirotchkine, Oxana Guerassimenko and Ilya Chumakov and is headquartered in Paris, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
ALPHA does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company